» Articles » PMID: 28195905

Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma

Overview
Journal Clin Nucl Med
Specialty Nuclear Medicine
Date 2017 Feb 15
PMID 28195905
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to evaluate the impact of intratumoral metabolic heterogeneity and quantitative FDG PET/CT imaging parameters for predicting patient outcomes in primary oropharyngeal squamous cell cancer (OPSCC).

Patients And Methods: We retrospectively investigated 105 patients with HPV-positive OPSCC. SUVmax and metabolic tumor volume (MTV) were measured for the primary tumors and when available for the metastatic sites. Primary tumor intratumoral metabolic heterogeneity was calculated as the area under a cumulative SUV volume histograms curve (AUC-CSH). The median follow-up time was 35.4 months (range, 3-92 months). Outcome end point was event-free survival (EFS). Kaplan-Meier survival plots and Cox regression analyses were performed.

Results: Of the 105 patients included, 19 patients relapsed and 11 deceased during the study period. AUC-CSH indexes were associated with EFS using PET gradient-based (P = 0.034) and 50% threshold (P = 0.02) segmentation methods, on multivariate analysis. Kaplan-Meier survival analysis using optimum cutoff of 16.7 SUVmax and 12.7 mL total MTV were significant predictors of EFS. Combining SUVmax and AUC-CSH index in 3 subgroups, patients with higher intratumoral heterogeneity and higher SUVmax were associated with worse outcome (log-rank, P = 0.026). Similarly, patients with higher intratumoral heterogeneity tumors and higher MTV had worse prognosis (log-rank, P = 0.022).

Conclusions: Intratumoral metabolic heterogeneity using FDG PET was a prognostic factor for EFS in patients with primary HPV (+) OPSCC. The combined predictive effect of FDG avidity, metabolic tumor burden, and intratumoral heterogeneity provided prognostic survival information in these patients.

Citing Articles

Neuroblastoma with high ASPM reveals pronounced heterogeneity and poor prognosis.

Li C, Lu X, Zhang F, Huang S, Ding L, Wang H BMC Cancer. 2024; 24(1):1151.

PMID: 39289658 PMC: 11406734. DOI: 10.1186/s12885-024-12912-4.


Whole-tumoral metabolic heterogeneity in F-FDG PET/CT is a novel prognostic marker for neuroblastoma.

Liu J, Ren Q, Xiao H, Li S, Zheng L, Yang X Cancer Imaging. 2024; 24(1):72.

PMID: 38863073 PMC: 11167917. DOI: 10.1186/s40644-024-00718-3.


Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [F]FDG PET/CT imaging: quantitative analysis of [F]FDG uptake in primary tumors and metastatic lymph nodes.

Wang D, Zhang X, Qiu B, Liu S, Zheng C, Fu J Eur J Nucl Med Mol Imaging. 2022; 49(13):4692-4704.

PMID: 35819498 DOI: 10.1007/s00259-022-05904-8.


The prognostic value of F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients.

Liu J, Si Y, Zhou Z, Yang X, Li C, Qian L Cancer Imaging. 2022; 22(1):32.

PMID: 35791003 PMC: 9254530. DOI: 10.1186/s40644-022-00472-4.


Tumor Glucose Metabolism and Its Heterogeneity on F-18 FDG PET/CT Provide Better Prognostication in Nonmetastatic Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma.

Cho H, Kim S, Jo K, Jeong Y, Kang W Cancers (Basel). 2021; 13(21).

PMID: 34771700 PMC: 8583647. DOI: 10.3390/cancers13215538.


References
1.
Kang S, Song H, Byun B, Oh J, Kim H, Hong S . Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer. Nucl Med Mol Imaging. 2014; 48(1):16-25. PMC: 4035157. DOI: 10.1007/s13139-013-0231-7. View

2.
Chang K, Tsang N, Liao C, Hsu C, Chung M, Lo C . Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma. J Nucl Med. 2012; 53(1):21-8. DOI: 10.2967/jnumed.111.090696. View

3.
Watabe T, Tatsumi M, Watabe H, Isohashi K, Kato H, Yanagawa M . Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT. Ann Nucl Med. 2011; 26(3):222-7. DOI: 10.1007/s12149-011-0562-3. View

4.
Hatt M, Majdoub M, Vallieres M, Tixier F, Rest C, Groheux D . 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2014; 56(1):38-44. DOI: 10.2967/jnumed.114.144055. View

5.
Yan J, Chu-Shern J, Loi H, Khor L, Sinha A, Quek S . Impact of Image Reconstruction Settings on Texture Features in 18F-FDG PET. J Nucl Med. 2015; 56(11):1667-73. DOI: 10.2967/jnumed.115.156927. View